Contact Details | Similar Products

Communicate with Supplier:

: Ms. Elaine: What can I do for you?

ENMD-2076 CAS NO.934353-76-1

Min.Order Quantity:: 1 Kilogram

Purity:: 98%

Port:: tianjin or Qingdao

Payment Terms:: L/C,T/T

Add to Inquiry Cart

Product Details

Keywords

ENMD-2076
ENMD-2076 price
ENMD-2076 supplier

Quick Details

ProName: ENMD-2076
CasNo: 934353-76-1
Molecular Formula: C21H25N7
Appearance: powder
Application: used in pharmaceutical intermediate
DeliveryTime: 3 days after receive your advanced pay...
PackAge: as client's required
Port: tianjin or Qingdao
ProductionCapacity: 10 Metric Ton/Month
Purity: 98%
Storage: Store in dry, dark and ventilated pla...
Transportation: as client's required
LimitNum: 1 Kilogram
package: as requested
delivery time: 3-7 days
port: as required
package: as required
LimitNum: 1 Gram
Brand: Luspharm

Superiority

our strength

we have clients throughout the world：

professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

our laboratoy

we have our own independent lab test center：

this makes sure that our technology support is reliable and authoritative.all of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.

our factory

high quality with competitive price：

we are manufacturer and can provide high quality products with factory price.

package & shipment

fast and safe delivery：

parcels can be sent out within 24 hours after payment.

tracking number is available secure and discreet shipment.

you have various choices of transportation methods.

Details

product information:

product name:	enmd-2076
synonyms:	6-(4-methyl-1-piperazinyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(1e)-2-phenylethenyl]-4-pyrimidinamine;enmd-2076;(e)-n-(5-methyl-1h-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine;6-(4-methyl-1-piperazinyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(1e)-2-phenylethenyl]-4-pyrimidinamine enmd-2076
cas:	934353-76-1
mf:	c21h25n7
mw:	375.4701
einecs:
product categories:	inhibitor;inhibitors
mol file:	934353-76-1.mol

enmd-2076 chemical properties

density

1.267

safety information

msds information

enmd-2076 usage and synthesis

description	enmd-2076 has selective activity against aurora a and flt3 with ic50 of 14 nm and 1.86 nm, 25-fold selective for aurora a than over aurora b and less potent to vegfr2/kdr and vegfr3, fgfr1 and fgfr2 and pdgfrα. phase 2.
features	multi-target, anti-proliferative, pro-apoptotic activity, anti-angiogenic.
in vitro	enmd-2076 indicates activity against multiple kinases involved in angiogenesis, including flt3, ret, flt4/vegfr3, src, ntrk1, csf1r/fms, lck, vegfr2/kdr, fgfr1/2, and pdgfrα with ic50 from 1.86-120 nm. enmd-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with ic50 from 0.025 to 0.7 μm, which induces apoptosis and g2/m phase arrest. enmd-2076 induces regression or complete inhibition of tumor growth in tumor xenograft models derived from breast, colon, melanoma, leukemia, and multiple myeloma cell lines. enmd-2076 is the l (+) tartrate salt of enmd-981693. enmd-2076 shows significant cytotoxicity against myeloma cell lines (im9, arh-77, u266, rpmi 8226, mm.1s, mm.1r, nci-h929) and primary cells with ic50 from 2.99 to 7.06 μm, which induces apoptosis. enmd-2076 indicates low cytotoxicity to haematopoietic progenitors. enmd-2076 inhibits the phosphoinositide 3-kinase/akt pathway and downregulates survivin and x-linked inhibitor of apoptosis. enmd-2076 also inhibits aurora a and b kinases, and induces g2/m cell cycle arrest.
in vivo	enmd-2076 has sustained inhibitory effects on the activation of flt3 as well as vegfr2/kdr and fgfr1/2 in ht29 xenograft model. enmd-2076 could prevent the formation of new blood vessels and regress formed vessels in mda-mb-231 xenograft model. oral treatment with enmd-2076 (50, 100, 200 mg/kg per day) inhibits the tumour growth in h929 human plasmacytoma xenografts, with significant reduction in phospho-histone 3 (ph3), ki-67, and angiogenesis, and also a significant increase in cleaved caspase-3.

company information:

hebei luspharm trading co., ltd. is a high-tech enterprise engages in manufacturing and marketing chemicals for international distribution,specialized in apis, advanced intermediates, botanical extract and color industry.

our goal is becoming leading position in global distribution and trading based on unique combination of technical skill,unrivaled supplier network, market knowledge and an absolute commitment to customer satisfaction.

under a management team with professional experiences in chemical development, a pathbreaking optimization in our r&d center,advanced multi-purpose manufacturing facility and large-scale production line with gmp workshop, we can supply finished synthesis as client requirements and be sure high quality products,low costs, adequate supply and integrated excellent services.

luspharm headquarters are located in shijiazhuang, china. hebei luspharm trading co., ltd. is in charge of all business of luspharm.

our mission and enthusiasm is introducing the high quality chinese ingredients to global customers, and becoming a bridge between the changing china and the changing needs of our clients.focus, then the best".

adhering to the tenet of "today's quality will open up tomorrow's market", insisting on the philosophy of "integrity, win-win", we would like to cooperate with friends at home and abroad for creating bright future.